Lustig, Samuel D.; Kodali, Sravan K.; Longo, Sharon L.; Kundu, Somanath; Viapiano, Mariano S. published the artcile< Ko143 reverses MDR in glioblastoma via deactivating P-glycoprotein, sensitizing a resistant phenotype to TMZ treatment>, Quality Control of 112-63-0, the main research area is reverses MDR glioblastoma deactivating P glycoprotein phenotype temozolomide treatment; BCRP; Ko143; P-glycoprotein; combinatorial treatment; drug resistance; temozolomide.
Over-expression of both P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) has been associated with multidrug-resistance in glioblastoma (GBM). Though previously studied broad-spectrum inhibitors of drug efflux pumps have failed to progress in clin. studies due to in vivo toxicity, research into clin. viable targeted inhibitors is needed. This study evaluated the effects of Ko143, a non-toxic analog of fumitremorgin C, on temozolomide (TMZ) efficacy in resistant glioblastoma stem cells. We used ATP-Glo assay to determine cell viabilities and flow cytometry to perform cell cycle anal. Comparative gene expression was analyzed through RT-qPCR. TMZ IC50 decreased 41.07% (p<0.01) in the resistant phenotype when delivered in combination with Ko143. Addnl., the TMZ-resistant phenotype (GBM146) displayed 44-fold greater P-gp expression than the TMZ-sensitive phenotype (GBM9) (p<0.01), yet a 0.6-fold lower BCRP expression. Ko143 potentiates TMZ efficacy and likely inhibits P-glycoprotein more potently than previously indicated. Further development of non-toxic, targeted inhibitors of drug efflux pumps for use in combinatorial chemotherapy may improve glioblastoma patient prognosis. Anticancer Research published new progress about Antitumor agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Quality Control of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics